- Home
- BNGO vs BOLT Comparison
BNGO vs BOLT Comparison
Compare BNGO & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNGO | BOLT |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 10.5M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BNGO | BOLT |
|---|---|---|
| Price | $1.12 | $4.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $6.33 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 135.4K | 27.6K |
| Earning Date | 03-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.84 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,000,735.00 | $7,690,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $24.27 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 26.26 | N/A |
| 52 Week Low | $1.06 | $0.26 |
| 52 Week High | $5.50 | $7.35 |
Technical Indicators
Market Signals| Indicator | BNGO | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 34.85 | 37.82 |
| Support Level | $1.06 | $0.28 |
| Resistance Level | $1.18 | $5.45 |
| Average True Range (ATR) | 0.05 | 0.40 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 30.53 | 16.35 |
Price Performance
Historical ComparisonAbout BNGO Bionano Genomics Inc.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.